GWP
QNCX icon

Gen-Wealth Partners’s Quince Therapeutics QNCX Stock Holding History

Gen-Wealth Partners’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Hold
165
– – ﹤0.01% 618
2026
Q1 		$3.35K Buy
+165
New +$33.1K ﹤0.01% 613

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Gen-Wealth Partners's QNCX Position: Q2 2026 in Review

Gen-Wealth Partners held its Quince Therapeutics (QNCX) position steady in Q2 2026 at 165 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #618.

Gen-Wealth Partners first reported a position in QNCX in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.35K in Q1 2026. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Gen-Wealth Partners held 165 shares of Quince Therapeutics worth $3K as of Q2 2026.
  • Gen-Wealth Partners left its Quince Therapeutics share count unchanged in Q2 2026.
  • Quince Therapeutics made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q2 2026, its #618 holding.
  • Gen-Wealth Partners first reported a position in Quince Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Gen-Wealth Partners's Quince Therapeutics position peaked at $3.35K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.